Skip to main content

Table 1 Descriptive characteristics of participants at ART initiation and 1 year post-initiation

From: Growth improvement following antiretroviral therapy initiation in children with perinatally-acquired HIV diagnosed in older childhood in Zimbabwe: a prospective cohort study

 

ART initiation

1 year post-initiation

Male, n(%)

Female, n(%)

Total, n(%)

Male, n(%)

Female, n(%)

Total, n(%)

N

146

156

302

114

112

226

Age (years)

 6–8

34 (23.2)

26 (16.7)

60 (19.9)

15 (13.2)

7 (6.3)

22 (9.7)

 9–11

46 (31.5)

61 (39.1)

107 (35.4)

34 (29.8)

36 (32.1)

70 (31.0)

 12–13

34 (23.3)

35 (22.4)

69 (22.9)

23 (20.2)

33 (29.5)

56 (24.8)

 14–17

32 (21.9)

33 (21.8)

66 (21.9)

42 (36.8)

36 (32.1)

78 (34.5)

HAZ

 Mean (SD) Range

−1.80 (1.18)

− 4.5 to 1.3

− 1.52 (1.08)

−5.0 to 1.4

−1.65 (1.13)

− 5.0 to 1.4

−1.76 (1.12)

− 4.2 to 1.1

−1.53 (1.08)

− 4.6 to 0.8

−1.65 (1.10)

− 4.6 to 1.1

 Below − 3

25 (17.1)

11 (7.1)

36 (11.9)

20 (17.5)

11 (9.8)

31 (13.7)

 − 3 to <− 2

29 (19.9)

40 (25.6)

69 (22.9)

20 (17.5)

23 (20.5)

43 (19.0)

 −2 to <−1

55 (37.7)

57 (36.5)

112 (37.1)

45 (39.5)

42 (37.5)

87 (38.5)

 −1 and above

37 (25.3)

48 (30.1)

85 (28.2)

29 (25.4)

36 (32.1)

65 (28.8)

 Stunted (<−2)

54 (37.0)

51 (32.7)

105 (34.8)

40 (35.1)

34 (30.4)

74 (32.7)

WAZ

 Mean (SD) range

−1.81 (1.22)

−4.3 to 0.4

−1.39 (1.11)

− 4.5 to 1.0

−1.59 (1.18)

− 4.5 to 1.0

−1.72 (1.13)

− 4.5 to 0.7

−1.17 (1.07)

− 4.2 to 0.9

−1.45 (1.13)

− 4.5 to 0.9

 Below −3

29 (20.6)

16 (10.3)

45 (15.2)

18 (16.1)

7 (6.4)

25 (11.3)

 −3 to <− 2

30 (21.3)

27 (17.4)

57 (19.3)

23 (20.5)

15 (13.8)

38 (17.2)

 −2 to <−1

39 (27.7)

53 (34.2)

92 (31.1)

38 (33.9)

37 (33.9)

75 (33.9)

 −1 and above

43 (30.5)

59 (38.1)

102 (34.5)

33 (29.5)

50 (45.9)

83 (37.6)

 Missing

5

1

6

2

3

5

 Underweight (<−2)

59 (41.8)

43 (27.7)

102 (34.5)

41 (36.6)

22 (18.5)

63 (28.5)

BAZ

 Mean (SD) range

−1.11 (1.17)

−4.6 to 1.4

−0.72 (1.06)

−4.3 to 1.3

−0.91 (1.12)

− 4.6 to 1.4

−0.97 (1.00)

−3.6 to 0.8

−0.42 (0.99)

− 2.9 to 1.6

− 0.70 (1.03)

− 3.6 to 1.6

 Below − 3

12 (8.4)

5 (3.2)

17 (5.7)

6 (5.3)

0

6 (2.7)

 −3 to <−2

14 (9.8)

14 (9.0)

28 (9.4)

11 (9.7)

9 (8.3)

20 (9.0)

 −2 to <−1

48 (33.6)

35 (22.6)

83 (27.9)

34 (30.1)

17 (15.6)

51 (23.0)

 −1 and above

69 (48.3)

101 (65.2)

170 (57.1)

62 (54.9)

83 (76.2)

145 (65.3)

 Missing

3

1

4

1

3

4

 Wasted (<−2)

26 (18.2)

19 (12.3)

45 (15.1)

17 (15.0)

9 (8.3)

26 (11.7)

CD4 count

 < 200

41 (30.4)

47 (32.2)

88 (31.3)

10 (14.7)

12 (16.4)

22 (15.6)

 200–349

44 (32.6)

46 (31.5)

90 (32.0)

4 (5.9)

13 (17.8)

17 (12.1)

 350–499

35 (25.9)

36 (24.7)

71 (25.3)

16 (23.5)

7 (9.6)

23 (16.3)

 500+

15 (11.1)

17 (11.6)

32 (11.4)

38 (55.9)

41 (56.2)

79 (56.0)

 Missing

11

10

21

46

39

85

Ever diagnosed with TB

 Yes

9 (6.2)

9 (5.8)

18 (6.0)

7 (6.1)

6 (5.4)

13 (5.8)

 Yes

50 (35.2)

36 (23.8)

86 (29.4)

41 (36.6)

23 (21.1)

64 (29.0)

Ever admitted to hospital

 Missing

4

5

9

   

Pubertal delay

 Yes

8 (15.1)

19 (26.8)

27 (21.8)

5 (11.4)

14 (24.1)

19 (18.6)

 Not eligible

93

85

178

70

54

124